Innovative Pharmaceutical Biotech Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was HKD 6.59 million compared to HKD 8.08 million a year ago. Net income was HKD 103.4 million compared to net loss of HKD 245.7 million a year ago.

Basic earnings per share from continuing operations was HKD 0.0677 compared to basic loss per share from continuing operations of HKD 0.1678 a year ago. Diluted loss per share from continuing operations was HKD 0.0082 compared to HKD 0.1678 a year ago.